Stay updated on Lenvatinib and Pembrolizumab in HCC Clinical Trial
Sign up to get notified when there's something new on the Lenvatinib and Pembrolizumab in HCC Clinical Trial page.

Latest updates to the Lenvatinib and Pembrolizumab in HCC Clinical Trial page
- Check4 days agoNo Change Detected
- Check12 days agoNo Change Detected
- Check19 days agoChange DetectedAdded the disease term Hepatocellular carcinoma and a Resources section linking to the Genetic and Rare Diseases Information Center. Updated the page revision from v3.4.3 to v3.5.0.SummaryDifference0.1%

- Check26 days agoChange DetectedAdded Revision: v3.4.3 and removed Revision: v3.4.2.SummaryDifference0.0%

- Check54 days agoChange DetectedPlain Language Summary added and page updated to Revision 3.4.2 with new dates; funding-status notice removed.SummaryDifference0.3%

- Check61 days agoChange DetectedAdded a government funding lapse notice and updated the site to revision v3.4.1. These changes are administrative and do not modify the trial details, eligibility criteria, endpoints, or study data.SummaryDifference0.2%

- Check68 days agoChange DetectedShow glossary is now displayed; Last Update Submitted that Met QC Criteria and Last Update Posted timestamps are displayed; No FEAR Act Data is shown and Revision indicator updated to v3.4.0. The previous items Last Update Submitted that met QC Criteria, Last Update Posted (Estimated), No FEAR Act data, and Revision: v3.3.4 were removed.SummaryDifference0.1%

- Check82 days agoChange DetectedThe page now shows Revision: v3.3.4 added and Revision: v3.3.3 removed.SummaryDifference0.0%

Stay in the know with updates to Lenvatinib and Pembrolizumab in HCC Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Lenvatinib and Pembrolizumab in HCC Clinical Trial page.